Virax Biolabs Group Limited Ordinary Shares
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, ot… Read more
Virax Biolabs Group Limited Ordinary Shares (VRAX) - Total Assets
Latest total assets as of September 2025: $5.72 Million USD
Based on the latest financial reports, Virax Biolabs Group Limited Ordinary Shares (VRAX) holds total assets worth $5.72 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Virax Biolabs Group Limited Ordinary Shares - Total Assets Trend (2020–2025)
This chart illustrates how Virax Biolabs Group Limited Ordinary Shares’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Virax Biolabs Group Limited Ordinary Shares - Asset Composition Analysis
Current Asset Composition (March 2025)
Virax Biolabs Group Limited Ordinary Shares's total assets of $5.72 Million consist of 76.1% current assets and 23.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 65.8% |
| Accounts Receivable | $30.65K | 0.5% |
| Inventory | $94.67K | 1.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $39.65K | 0.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Virax Biolabs Group Limited Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Virax Biolabs Group Limited Ordinary Shares's current assets represent 76.1% of total assets in 2025, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 65.8% of total assets in 2025, down from 100.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 1.5% of total assets.
Virax Biolabs Group Limited Ordinary Shares Competitors by Total Assets
Key competitors of Virax Biolabs Group Limited Ordinary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Virax Biolabs Group Limited Ordinary Shares - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Virax Biolabs Group Limited Ordinary Shares generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Virax Biolabs Group Limited Ordinary Shares is currently not profitable relative to its asset base.
Virax Biolabs Group Limited Ordinary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.35 | 11.58 | 0.02 |
| Quick Ratio | 11.21 | 11.20 | 0.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.78 Million | $ 7.34 Million | $ -303.78K |
Virax Biolabs Group Limited Ordinary Shares - Advanced Valuation Insights
This section examines the relationship between Virax Biolabs Group Limited Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.30 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | 17.2% |
| Total Assets | $6.43 Million |
| Market Capitalization | $1.24 Million USD |
Valuation Analysis
Below Book Valuation: The market values Virax Biolabs Group Limited Ordinary Shares's assets below their book value (0.19 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Virax Biolabs Group Limited Ordinary Shares's assets grew by 17.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Virax Biolabs Group Limited Ordinary Shares (2020–2025)
The table below shows the annual total assets of Virax Biolabs Group Limited Ordinary Shares from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $6.43 Million | +17.19% |
| 2024-03-31 | $5.48 Million | -44.11% |
| 2023-03-31 | $9.81 Million | +20046.22% |
| 2022-03-31 | $48.71K | -48.25% |
| 2021-03-31 | $94.12K | +316.29% |
| 2020-03-31 | $22.61K | -- |